Literature DB >> 18378801

Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine.

Patrick L Sheets1, Cara Heers, Thomas Stoehr, Theodore R Cummins.   

Abstract

Voltage-gated sodium channels play a critical role in excitability of nociceptors (pain-sensing neurons). Several different sodium channels are thought to be potential targets for pain therapeutics, including Na(v)1.7, which is highly expressed in nociceptors and plays crucial roles in human pain and hereditary painful neuropathies, Na(v)1.3, which is up-regulated in sensory neurons following chronic inflammation and nerve injury, and Na(v)1.8, which has been implicated in inflammatory and neuropathic pain mechanisms. We compared the effects of lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], a new pain therapeutic, with those of lidocaine and carbamazepine on recombinant Na(v)1.7 and Na(v)1.3 currents and neuronal tetrodotoxin-resistant (Na(v)1.8-type) sodium currents using whole-cell patch-clamp electrophysiology. Lacosamide is able to substantially reduce all three current types. However, in contrast to lidocaine and carbamazepine, 1 mM lacosamide did not alter steady-state fast inactivation. Inhibition by lacosamide exhibited substantially slower kinetics, consistent with the proposal that lacosamide interacts with slow-inactivated sodium channels. The estimated IC(50) values for inhibition by lacosamide of Na(v)1.7-, Na(v)1.3-, and Na(v)1.8-type channels following prolonged inactivation were 182, 415, and 16 microM, respectively. Na(v)1.7-, Na(v)1.3-, and Na(v)1.8-type channels in the resting state were 221-, 123-, and 257-fold less sensitive, respectively, to lacosamide than inactivated channels. Interestingly, the ratios of resting to inactivated IC(50)s for carbamazepine and lidocaine were much smaller (ranging from 3 to 16). This suggests that lacosamide should be more effective than carbamazepine and lidocaine at selectively blocking the electrical activity of neurons that are chronically depolarized compared with those at more normal resting potentials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378801     DOI: 10.1124/jpet.107.133413

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  73 in total

1.  In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.

Authors:  Yuying Wang; Joel M Brittain; Brian W Jarecki; Ki Duk Park; Sarah M Wilson; Bo Wang; Rachel Hale; Samy O Meroueh; Theodore R Cummins; Rajesh Khanna
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

2.  The acute and chronic effects of the novel anticonvulsant lacosamide in an experimental model of status epilepticus.

Authors:  Claude G Wasterlain; Thomas Stöhr; Alain Matagne
Journal:  Epilepsy Res       Date:  2011-01-28       Impact factor: 3.045

3.  VOLTAGE-GATED CALCIUM CHANNELS ARE NOT AFFECTED BY THE NOVEL ANTI-EPILEPTIC DRUG LACOSAMIDE.

Authors:  Yuying Wang; Rajesh Khanna
Journal:  Transl Neurosci       Date:  2011-03       Impact factor: 1.757

4.  The structure-activity relationship of the 3-oxy site in the anticonvulsant (R)-N-benzyl 2-acetamido-3-methoxypropionamide.

Authors:  Pierre Morieux; Christophe Salomé; Ki Duk Park; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

5.  The tetrodotoxin-resistant Na+ channel Na (v)1.8 reduces the potency of local anesthetics in blocking C-fiber nociceptors.

Authors:  Katrin Kistner; Katharina Zimmermann; Corina Ehnert; Peter W Reeh; Andreas Leffler
Journal:  Pflugers Arch       Date:  2010-02-23       Impact factor: 3.657

6.  Sidedness of carbamazepine accessibility to voltage-gated sodium channels.

Authors:  Sooyeon Jo; Bruce P Bean
Journal:  Mol Pharmacol       Date:  2013-12-06       Impact factor: 4.436

7.  (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.

Authors:  Aubin Moutal; Liberty François-Moutal; Samantha Perez-Miller; Karissa Cottier; Lindsey Anne Chew; Seul Ki Yeon; Jixun Dai; Ki Duk Park; May Khanna; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2015-04-07       Impact factor: 5.590

8.  Block of human cardiac sodium channels by lacosamide: evidence for slow drug binding along the activation pathway.

Authors:  Ging Kuo Wang; Sho-Ya Wang
Journal:  Mol Pharmacol       Date:  2014-02-21       Impact factor: 4.436

9.  Identification of the benzyloxyphenyl pharmacophore: a structural unit that promotes sodium channel slow inactivation.

Authors:  Amber M King; Xiao-Fang Yang; Yuying Wang; Erik T Dustrude; Cindy Barbosa; Michael R Due; Andrew D Piekarz; Sarah M Wilson; Fletcher A White; Christophe Salomé; Theodore R Cummins; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2012-09-19       Impact factor: 4.418

Review 10.  Voltage-gated sodium channels: pharmaceutical targets via anticonvulsants to treat epileptic syndromes.

Authors:  Mena Abdelsayed; Stanislav Sokolov
Journal:  Channels (Austin)       Date:  2013-03-26       Impact factor: 2.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.